Rapid infusion of ofatumumab appears safe and reduces infusion related reactions in patients with relapsed/refractory Chronic Lymphocytic Leukemia

Anti-CD20 monoclonal antibodies, such as ofatumumab and rituximab, have been demonstrated to be effective in B-cell Lymphoma and CLL. However, the recommended administration of ofatumumab for CLL requires lengthy infusion times and side effects are common during and after infusion. On 7th July 2017, in The Oncologist, William Donnellan, MD, from the Sarah Cannon Research […]

Read More